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Abstract Exercise poses significant challenges to glucose
management in type 1 diabetes. In spite of careful planning
and manipulation of subcutaneous insulin administration,
increased risk of hypoglycaemia and glycaemic variability
during and after exercise may occur as a result of inherent
delays in insulin action and impaired counter-regulatory
hormone responses. Various strategies to mitigate this issue
have been advocated in clinical practice, including ingestion
of supplementary carbohydrate prior to exercise, reducing
background and pre-meal insulin bolus and performing bouts
of resistance/high intensity exercise before aerobic exercise.
Insulin pump therapy, considered the most physiological form
of insulin replacement for type 1 diabetes allows modulation
of basal insulin delivery before, during and after exercise.
However uncertainty remains regarding the optimal strategy
to reduce basal insulin delivery and its efficacy. In this issue of
Diabetologia, McAuley and colleagues (DOI: 10.1007/
s00125-016-3981-9) report on the impact of a 50%
reduction of basal insulin delivery before, during and after
moderate-intensity aerobic exercise. Results from this study
may contribute to a better understanding of the effects of basal
insulin delivery manipulation and may aid in devising
therapeutic approaches for glucose management during
exercise.
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Insulin pump therapy is widely considered to be the most
physiological form of insulin replacement for people with type
1 diabetes. It facilitates flexible modulation of basal insulin
requirements and allows the user to temporarily change basal
insulin delivery before and during periods of enhanced or
reduced insulin sensitivity, such as in exercise or intercurrent
illness. Despite perceived benefits, the frequency of insulin
pump therapy varies widely in different European countries,
from below 5% to up to about 25% [1].
Regular physical activity in individuals with type 1
diabetes is associated with several health benefits, including
improved fitness and quality of life, improved insulin
sensitivity, reduced lipid levels, and lower rates of micro-
and macrovascular complications and mortality [2]. Despite
the reported benefits and progress in its management, physical
exercise remains a challenge for many because of the
dysglycaemia that occurs either during or after exercise. Few
scientifically rigorous studies have explored how to prevent
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this from occurring, therefore the evidence-base for patient
guidance remains suboptimal. In this issue ofDiabetologia,
McAuley et al [3] report the effects of reducing insulin
pump basal rate by 50% 1 h before exercise, on glucose
and insulin levels, providing new insights to help inform
clinical practice.
In health, exercise causes major changes in glucose
production and utilisation, underpinned by rapid changes in
circulating insulin, glucagon, catecholamines and other
counter-regulatory hormones. Studies in healthy individuals
highlight several processes contributing towards glucose
turnover during exercise. These include mobilisation of
glucose into exercising skeletal muscle via upregulation of
insulin-dependent and independent glucose transporters
(e.g. GLUT4) [4] and changes in exercise-associated fuel
metabolism. The risk of hypoglycaemia associated with the
increase in exercise-induced insulin sensitivity is mitigated
through reduction of endogenous insulin production, which
additionally mediates increased glycogenolysis and fatty acid
oxidation.
Exercise poses several challenges to individuals with type
1 diabetes. Manipulating externally administered insulin, with
inherent delays in absorption and action can be difficult and
requires careful planning. Impaired counter-regulatory
responses and inappropriately high insulin levels increase
the risk of hypoglycaemia during or after exercise. Fear of
hypoglycaemia may cause overcompensation by ingesting
excessive amounts of carbohydrate or reducing insulin doses
to a greater degree than necessary, leading to high glucose
levels during or after exercise. However, a number of
alternative strategies have been developed to limit the
hypoglycaemia associated with exercise in type 1 diabetes
(see text box) [5].
Strategies to limit exercise-induced hypoglycaemia in
type 1 diabetes
1. Supplementary carbohydrate intake prior to exercise,
without or with reduced dose bolus insulin
2. Reducing pre-exercise basal insulin (this is more
difficult for those using insulin injections)
3. Reducing pre-meal insulin bolus for exercise that occurs
within 2–3 h of a meal
4. Reducing post exercise basal/bolus insulin to reduce risk
of nocturnal or delayed post exercise hypoglycaemia
5. Performing bouts of resistance/high intensity exercise
before aerobic exercise
6. Use of novel technology, such as continuous glucose
monitoring systems to guide insulin reduction and
ingestion of additional carbohydrates
Insulin pump therapy allows the user to temporarily reduce
or suspend insulin delivery, providing greater flexibility. This
may be particularly useful for individuals undertaking
unplanned physical activity and exercise, as well as those
who carry out routine physical activity. As a result of delays
in the absorption of subcutaneously delivered insulin,
however, the effect of insulin delivery rate adjustment is not
immediate and, therefore, adjustment prior to exercise related
activity is usually recommended. However, clinical advice
and guidelines on insulin pump management during exercise
varies because of the low level of evidence available.
In spite of current guidelines and diabetes technology such
as insulin pump therapy and continuous glucose monitoring,
avoiding exercise related dysglycaemia remains a challenge
for many individuals with type 1 diabetes. Factors
contributing to such complexity include inter- and
intra-individual variability in insulin requirements and
absorption, timing, exercise type (e.g. aerobic vs anaerobic,
start/stop, resistance), intensity and duration of exercise,
amount of active insulin on board, antecedent hypoglycaemia,
counter-regulatory hormone responses and the changes in
insulin sensitivity induced by exercise itself. The effects of
varying insulin pump adjustments in type 1 diabetes have
been previously reported [6], but uncertainty still exists
because of the heterogeneity of experimental conditions and
exercise modality used, and reproducibility outside of
controlled study environments.
The study by McAuley and colleagues investigated the
impact of a 50% reduction of basal insulin delivery 1 h before,
during and after moderate-intensity aerobic exercise (30-min
of stationary cycling) in the fasting state, in a randomised
crossover study design [3]. The results of this study
highlighted some interesting findings and relevant key points
for healthcare professionals looking after physically active
insulin pump users. The first point is what most insulin pump
users and diabetes healthcare professionals have experienced
in practice: that in conditions where blood glucose levels are
low–normal at the start of exercise, reducing basal insulin
delivery (even by 50%) does not always mitigate against
hypoglycaemia. Further reduction or suspension of insulin
delivery coupled with ingestion of carbohydrate beforehand
may be necessary, with further carbohydrate supplementation
to avoid hypoglycaemia, depending on prevailing blood
glucose levels during and after exercise.
The second finding relates to the primary endpoint of the
study, namely, circulating free insulin levels. These are
increased, albeit transiently, during moderate-intensity
exercise, in spite of halving basal insulin delivery 1 h
pre-exercise. A plausible explanation is provided by the
authors for this finding: increased cutaneous blood flow.
Augmented absorption of subcutaneous human and analogue
insulin during exercise and at varying ambient temperatures
have been reported [7]. Most studies, however, assessed
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subcutaneous insulin injection rather than continuous insulin
pump infusion and so the effects of the latter on insulin
pharmacokinetics and pharmacodynamics during exer-
cise have not been well elucidated. The final key find-
ing from McAuley and colleagues is the accelerated
reduction in free insulin levels observed immediately
post-exercise, postulated to be due to the declining sub-
cutaneous insulin reservoir after exercise and basal in-
sulin delivery reduction. The difference in free insulin
levels after exercise was significant in the immediate
recovery period (measured by plasma insulin AUC,
p= 0.028, as shown in the electronic supplementary ma-
terial [ESM] Table 1 of the article [3]), with subsequent
modest increase in plasma glucose level post-exercise
compared with rest. Hyperglycaemia during exercise in
insulin pump users has been reported previously, al-
though this was following a short period of intense ex-
ercise (80% V˙O2max) and without significant changes to
plasma free insulin levels [8].
How does this study influence our understanding of
exercise and glucose management in insulin pump users,
and what are its implications for clinical practice? The rise
in circulating free insulin observed in this study needs further
evaluation to increase our understanding of the potential
mechanisms associated with this outcome and to determine
the clinical implications. It is also important to establish
whether the same pharmacokinetic findings occur with
different exercise modalities (e.g. in resistance or submaximal
exercise) and in various populations (e.g. different age groups
and ranging participant characteristics) to determine the
generalisability of these study outcomes. The authors
hypothesised that, despite increased circulating free insulin
levels, the modest rise in glucose with exercise may have
been due to the effects of counter-regulatory hormones and
that sustainment of glucose levels during recovery may
have been due to the decline in insulin levels post-exercise.
Combining the glucose level results with data on counter-
regulatory hormone and glucose turnover (neither of which
were assessed in this study) may help to elucidate the
hormonal and metabolic interactions between the three
and indicate clinical implications, especially in physically
active insulin pump users with impaired counter-
regulation. A recent study reported that during intermittent
high-intensity exercise in type 1 diabetes without insulin
delivery adaption, reduced exogenous glucose require-
ments may occur secondary to decreased glucose uptake
and disposal, rather than increased hepatic glucose output
or muscle glycogen utilisation [9]. This potentially novel
mechanism warrants further investigation to further our
understanding of exercise metabolic adaptation.
Future exercise studies in type 1 diabetes following insulin
delivery adjustments should include evaluation of blood
glucose levels over longer periods post-exercise since delayed
hypoglycaemia, particularly overnight, remains a clinical
concern. Such studies should recruit participants with
impaired hypoglycaemia awareness and antecedent
hypoglycaemia events, who have an increased risk of
hypoglycaemia. In addition to pre-exercise insulin deliv-
ery interventions, studies comparing or combining this
strategy with novel hypoglycaemia avoidance strategies,
such as threshold/predictive suspended insulin pump
management [10], intermittent high intensity exercise
or acute caffeine ingestion [11], may help uncover man-
agement approaches best suited for individuals with a
variety of characteristics and requirements. A novel ap-
proach, using the artificial pancreas, has reported im-
provements in glycaemic control during free daily living
home studies [12], but further technological develop-
ment is needed to optimise its efficacy during exercise.
Gathering evidence from well-designed studies reflecting
‘real world’ conditions may ultimately help healthcare
professionals to better understand and safely optimise
therapeutic management during exercise.
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